Is Newron Pharmaceuticals S.p.A. (0QOI.L) a Buy, Sell, or Hold?
LSE : 0QOI.L
Newron Pharmaceuticals S.p.A.
$11.65518 CHF
-$0.14 (-1.23%)
- Volume
- 116.5K
- Average Volume
- 4.22K
- Market Capitalization
- $233.23M
- P/E Ratio
- -18.95
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $12.00
- Year Low
- $4.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.76
Company Overview
LSE
Stefan Weber
Biotechnology
Healthcare
0QOI.L
22
IT
CHF
Liquidity Metrics
-3.43
0.76
0.76
0.24
0.00
Sales & Valuation
$19.25M
13.88
-22.91
8.31
1.60
Profitability
-$0.67
-$13.33M
-69.29%
-64.66%
277.88%
-33.13%
P/E Metrics
-18.95
0.11
0.11
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
5.49
7/9
-$12.04M
$40.02M
$51.15M
$21.47M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Roberto Galli | Chief Financial Officer |
| Laura Faravelli | Vice President of Business Development |
| Filippo Moriggia | Vice President of Operations |
| Stefan Weber | Chief Executive Officer & Executive Director |
| Ravi Anand | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Newron Pharmaceuticals S.p.A. (LSE:0QOI.L) Stock
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, focused on discovering and advancing novel therapeutic solutions for central and peripheral nervous system disorders, as well as pain management. Its operations are concentrated in Italy and the United States. The company currently markets Xadago (safinamide) for Parkinson's disease and is further developing it to address levodopa-induced dyskinesia. Its developmental pipeline also includes Evenamide, targeting schizophrenia and its treatment-resistant variants, along with Ralfinamide, an orphan drug candidate for neuropathic pain. Established in 1999, Newron Pharmaceuticals S.p.A. maintains its headquarters in Bresso, Italy. ...
Frequently Asked Questions
-
What is the current Newron Pharmaceuticals S.p.A. (0QOI.L) stock price?
-
Newron Pharmaceuticals S.p.A.(LSE:0QOI.L) stock price is $11.65518 in the last trading session. During the trading session, 0QOI.L stock reached the peak price of $12 while $4.12 was the lowest point it dropped to. The percentage change in 0QOI.L stock occurred in the recent session was --1.23% while the dollar amount for the price change in 0QOI.L stock was -$0.14.
-
0QOI.L's industry and sector of operation?
-
The LSE listed 0QOI.L is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 0QOI.L?
-
Roberto Galli | Chief Financial Officer
Laura Faravelli | Vice President of Business Development
Filippo Moriggia | Vice President of Operations
Stefan Weber | Chief Executive Officer & Executive Director
Ravi Anand | Chief Medical Officer -
How many employees does 0QOI.L have?
-
Number of 0QOI.L employees currently stands at 22. 0QOI.L operates from Via Antonio Meucci 3, Bresso, MI 20091, IT.
-
Link for 0QOI.L official website?
-
Official Website of 0QOI.L is: https://www.newron.com
-
How do I contact 0QOI.L?
-
0QOI.L could be contacted at phone #39 02 610 3461 and can also be accessed through its website. 0QOI.L operates from Via Antonio Meucci 3, Bresso, MI 20091, IT.
-
How many shares of 0QOI.L are traded daily?
-
The average number of 0QOI.L shares traded daily for last 3 months was 4.22K.
-
What is the market cap of 0QOI.L currently?
-
The market value of 0QOI.L currently stands at $233.23M with its latest stock price at $11.65518